A phase II, multicenter, open-label study of polyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301).

被引：0
|
作者：
Hubbard, Joleen M.
Ahn, Daniel H.
Jones, Jeremy Clifton
Zhu, Mojun
Wittenberger, Kathleen
Csiszovszki, Zsolt
Somogyi, Eszter
Lorincz, Orsolya
Molnar, Levente
Toth, Jozsef
Youssoufian, Hagop
Toke, Eniko Rita
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Mayo Clin, Div Med Oncol, Phoenix, AZ USA
[3] Mayo Clin Florida, Jacksonville, FL USA
[4] Mayo Clin Rochester, Dept Med Oncol, Rochester, MN USA
[5] TreosBio, Veszprem, Hungary
[6] Treos Bio, Veszprem, Hungary
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3594
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Randomized Phase II Open-Label Study of mFOLFOX6 in Combination With Linifanib or Bevacizumab for Metastatic Colorectal Cancer
    O'Neil, Bert H.
    Cainap, Calin
    Van Cutsem, Eric
    Gorbunova, Vera
    Karapetis, Christos S.
    Berlin, Jordan
    Goldberg, Richard M.
    Qin, Qin
    Qian, Jiang
    Ricker, Justin L.
    Fischer, JuDee
    McKee, Mark D.
    Carlson, Dawn M.
    Kim, Tae Won
    CLINICAL COLORECTAL CANCER, 2014, 13 (03) : 156 - 163
  • [32] Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer
    O'Neil, Bert H.
    Cainap, Calin
    Van Cutsem, Eric
    Gorbunova, Vera A.
    Karapetis, Christos Stelios
    Berlin, Jordan
    Goldberg, Richard M.
    Qin, Qin
    Qian, Jiang
    Ricker, Justin L.
    McKee, Mark D.
    Carlson, Dawn M.
    Kim, Tae Won
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial
    Cousin, Sophie
    Cantarel, Coralie
    Guegan, Jean-Philippe
    Gomez-Roca, Carlos
    Metges, Jean-Philippe
    Adenis, Antoine
    Pernot, Simon
    Bellera, Carine
    Kind, Michele
    Auzanneau, Celine
    Le Loarer, Francois
    Soubeyran, Isabelle
    Bessede, Alban
    Italiano, Antoine
    CLINICAL CANCER RESEARCH, 2021, 27 (08) : 2139 - 2147
  • [34] Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study
    Atkins, Michael B.
    Gravis, Gwenaelle
    Drosik, Kazimierz
    Demkow, Tomasz
    Tomczak, Piotr
    Wong, Shirley S.
    Michaelson, M. Dror
    Choueiri, Toni K.
    Wu, Benjamin
    Navale, Lynn
    Warner, Douglas
    Ravaud, Alain
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (30) : 3431 - +
  • [35] A phase II study of cadonilimab plus FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
    Lin, R.
    Zhao, S.
    Su, L.
    Hong, Y.
    Luo, J.
    Wei, Y.
    Zhao, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1519 - S1519
  • [36] Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Characterization of the circulating immune response in the AVETUXIRI phase II trial
    Benidovskaya, E.
    Huyghe, N.
    Carrasco, J.
    De Cuyper, A.
    Sinapi, I.
    Verstraelen, E.
    Goffette, P.
    Ghaye, B.
    Papier, M.
    van Maanen, A.
    Castella, M-L.
    Galon, J.
    van den Eynde, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S56 - S56
  • [37] Phase II study of ipilimumab, nivolumab, and panitumumab in patients with KRAS/NRAS/BRAF wild-type (WT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
    Lee, Michael Sangmin
    Loehrer, Patrick J.
    Imanirad, Iman
    Cohen, Stacey
    Ciombor, Kristen Keon
    Moore, Dominic T.
    Carlson, Cheryl Ann
    Sanoff, Hanna Kelly
    McRee, Autumn Jackson
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [38] Amivantamab monotherapy in relapsed/refractory metastatic colorectal cancer: OrigAMI-1, an open-label, phase 1b/2 study
    Oberstein, Paul Eliezer
    Moreno, Victor
    Raghav, Kanwal Pratap Singh
    Hong, Yong Sang
    Han, Sae-Won
    Su, Yu-Li
    Yuan, Ying
    Pietrantonio, Filippo
    Van Cutsem, Eric
    Eng, Cathy
    Curtin, Joshua C.
    Chowdhury, Sanjib
    Bhattacharya, Rianka
    Maul, Raymond Scott
    Iwasawa, Ryota
    Schnepp, Robert W.
    Knoblauch, Roland Elmar
    Thayu, Meena
    Ho, Gwo Fuang
    Kim, Han Sang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 135 - 135
  • [39] A Phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer.
    Cartwright, TH
    Lopez, T
    Vukelja, SJ
    Encarnacion, C
    Boehm, KA
    Asmar, L
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 284S - 284S
  • [40] A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer.
    Blackwell, KL
    Kaplan, EH
    Franco, SX
    Marcom, PK
    Maleski, JE
    Sorensen, MJ
    Berger, MS
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 196S - 196S
12345